nivolumab

targets

all catalysts(86)

News(10)

• J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
  Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio bu…
  biospace · 4d ago
• BMS’ Phase 3 win for lung drug clouded by high-dose miss
  A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awa…
  biospace · 6d ago
• BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
  Bristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth.
  fiercebiotech · 6d ago
• Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset
  Japan’s Ono Pharmaceutical is paying $80 million upfront for the regional rights to a trio of Biohaven’s IgG degraders, led by a phase 3-stage Grave’s disease prospect.
  fiercebiotech · 10d ago
• Q3 layoffs down YOY, with 90% fewer biopharma employees affected
  Big Pharma companies including Bristol Myers Squibb, Johnson & Johnson and Novartis are among those that made or planned layoffs in Q3. Those cuts could affect over 1,800 employees, with New Jersey…
  biospace · 10d ago
• Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
  A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.
  biopharma_dive · 11d ago
• Significant stock movers of September: Viking soars, Longeveron slides
  Viking Therapeutics rode strong obesity data before a major capital raise, while Longeveron’s mid-stage setback prompted questions about its future.
  biospace · 13d ago
• BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
  BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…
  biospace · 16d ago
• Unlocking cell surface protein research with site-specific labeling
  Applications in flow cytometry, cell sorting, target validation, and therapeutic discovery
  biospace · 1mo ago
• 5 drugmakers chasing Merck and Moderna in the cancer vaccine race
  Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…
  biospace · 1mo ago